Dermatological diseases affect millions of people worldwide each year, impacting their quality of life, and emotional well-being. Despite this, and despite progress in the development of biologic therapies to treat dermatological diseases, the vast majority of dermatology patients continue to be treated by older therapies that often do not provide adequate efficacy, do not target specific disease mediators, or that carry with them substantial safety and tolerability issues.

Dermatologists and patients need innovative topical treatments that target validated molecular mediators of disease with high local skin efficacy, low systemic and topical safety risks, the ability to use chronically, and with a good high risk/benefit ratio.